Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million